Delgado-Goñi, Teresa http://orcid.org/0000-0001-6078-9291
Galobart, Teresa Casals
Wantuch, Slawomir
Normantaite, Deimante
Leach, Martin O.
Whittaker, Steven R. http://orcid.org/0000-0001-9062-7947
Beloueche-Babari, Mounia
Funding for this research was provided by:
RCUK | Medical Research Council (MR/K011057/1, MR/K011057/1, MR/K011057/1, MR/K011057/1)
Cancer Research UK (C1060/A10334, C1090/A16464, C1060/A10334, C1090/A16464, C1060/A10334, C1090/A16464, C1060/A10334, C1090/A16464, C1060/A10334, C1090/A16464, C1060/A10334)
Start-up funds from The Institute of Cancer Research.
Article History
Received: 24 April 2019
Revised: 5 September 2019
Accepted: 23 October 2019
First Online: 10 December 2019
Competing interests
: The authors declare no competing interests.
: This study used exclusively already published gene expression datasets from anonymised patients<sup>21–23</sup> and no animal work was involved. The A375 human melanoma cell line was acquired from the American Tissue Type Collection: A375 (BRAFV600E). The 3 resistant clones (R6, B4 and D9) were generated in our group after continuous vemurafenib exposure of the A375 parental line as described in the methods section. All the clones, including the parental line, were tested by STR profiling on the 7 September 2016.
: T.D-G. and S.Wantuch were supported by MRC project grant (MR/K011057/1), T.C-G., D.N., M.O.L. and M.B-B. were supported by a CRUK Centre for Cancer Imaging grant C1090/A16464. S.R.Whittaker is supported by start-up funds from The Institute of Cancer Research. We also acknowledge grant C1060/A10334 from CRUK and EPSRC Cancer Imaging Centre in association with the MRC and Department of Health (England). M.O.L. is a NIHR Emeritus Senior Investigator.
: The datasets generated and analysed during the current study are not publicly available but available from the corresponding authors on reasonable request.